Perlara
Perlara: building the YC for rare disease parents
- Founded
- 2014
- Status
- Active
- Stage
- Early
- Team size
- 1
- Location
- San Francisco, CA, USA; Oakland
- Category
- AI Clinical Operations
- Sector
- Drug Discovery and Delivery
About Perlara
Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively. Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech
Federal research funding
1 NIH award totalling $1,016,229, FY2025.
- REMIT (Rescue Mitochondrial Therapeutics): Unlocking Broad-Spectrum Mitochondrial Rescuers
Source: NIH RePORTER.
Securities filings
1 Form D filing on record, 2017.
Filed as Perlara PBC
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
